ASSESSMENT OF RADIOTHERAPY IN HUMAN NEOPLASMS

一种或多种治疗方式的选择（例如，辐射 治疗，化疗和手术）已经根据经验得出 基于这些药物在既往接受过治疗的患者中的试验。 然而，在个别情况下，人们无法预测是否 肿瘤对治疗有反应的程度 反应 因此，个别患者可能会受到 长期的治疗过程， 无效或可能被拒绝潜在有用的治疗，因为 肿瘤不会有反应的概率 它 希望有一种非侵入性的体内系统来预测 一个人是否会对治疗有反应，因此， 优化治疗过程 利用新实施的（1）体内磁共振 在1.4T全身成像仪上进行MRS，我们打算 表征磷代谢物的改变， 放射治疗对肿瘤细胞内pH值影响 并将MRS结果与临床终点相关联。 在 为了获得这些研究的统计学意义， 鳞状细胞癌患者人群数量 或淋巴瘤（霍奇金或非霍奇金将参与这项研究）。 项目 MRS数据将进一步与 非整倍体和整倍体群体的分布， 流式细胞术测定DNA含量。 的mri 还将进行测量以识别边界， 肿瘤的不均匀性和中心坏死。 组织病理 并会就每宗个案进行分析。 人们希望 人类的一些生化过程和放射生物学 肿瘤对分次γ射线照射的反应 还将描述方案。 最终， 来预测治疗是否能控制肿瘤 MRS谱中的特征变化，并且可以更多地 合理选择主要形式，并决定是否需要 一种或多种辅助疗法（例如，手术、化疗等）

The selection of one or more treatment modalities (e.g., radiation therapy, chemotherapy and surgery) has been empirically derived based on trials with these agents in previously treated patients. However, in the individual case one cannot predict whether or not that tumor will respond to treatment nor the extent of that response. As a consequence, individual patients may be subjected to a protracted course of therapy which ultimately may be ineffective or may be denied a potentially useful therapy because of the statistical likelihood that the tumor will not respond. It would be desirable to have a noninvasive in vivo system to predict whether an individual will respond to treatments and, therefore, optimize the course of therapy. Utilizing the newly implemented (1) in vivo magnetic resonance spectroscopy (MRS) on a 1.4T wholebody imager, we intend to characterize the alterations of phosphorous metabolites and intracellular pH of human neoplasms in response to radiotherapy and correlate the MRS findings with the clinical end points. In order to obtain a statistical significance of these studies, a large number of patient population with either squamous cell carcinoma or lymphoma (Hodgkin or nonHodgkin will participate in this project. The MRS data will be further correlated to the distribution of aneuploid and euploid populations obtained from the measurement of DNA content by flow cytometry. The MRI measurements will also be made to identify the boundary, inhomogeneity and central necrosis of tumors. Histopathological analysis will also be performed for each case. It is hoped that some of the biochemical processes and radiobiology of human neoplasms in response to the fractionated gammairradiation regimen will also be delineated. Ultimately it would be possible to predict whether the treatments will control the tumor base on the characteristic changes in the MRS spectra, and one may more rationally choose the primary modality and decide the need for one or more adjuvant therapies (e.g., surgery, chemotherapy, etc.)